CTRI/2025/06/089367 [Registered on: 23/06/2025] Trial Registered Prospectively
Last Modified On:
18/07/2025
Post Graduate Thesis
No
Type of Trial
Interventional
Type of Study
Drug
Study Design
Randomized, Parallel Group, Active Controlled Trial
Public Title of Study
Study to Investigate the Efficacy and Safety of Semaglutide of Intas Compared to Wegovy FlexTouch in Overweight and Obese Adult Participants in Adjunct to Diet and Exercise
Scientific Title of Study
A Prospective, Phase 3, Randomized, Interventional, Open-label,
Parallel-Group, Multicentre, Active Controlled Study to Establish Noninferiority
of Intas Semaglutide Subcutaneous Injection (Test) Against
Innovator Semaglutide (Wegovy FlexTouch, Novo Nordisk) Subcutaneous
Injection (Reference) in Overweight and Obese Adult Participants in Adjunct to
Diet and Exercise
Department of Clinical research, Room No. NA, Mandi, Dabwali road, bathinda, Punjab151001
Bathinda PUNJAB
9464739943
shivani66sidana@gmail.com
Dr Henil Shah
Anand surgical Hospital pvt. ltd
Department of Clinical research, Room No. NA, Memco cross road, Naroda road, Ahmedabad-382345, Gujarat, India
Ahmadabad GUJARAT
7096038345
drhenilshah.research@gmail.com
Dr Paramesh Shamanna
Bangalore Clinisearch
Department of Clinical research, Room No. NA, No.416, 4th Block, Kalyan Nagar, Bangalore - 560043 Bangalore, KARNATAKA
Bangalore KARNATAKA
9845010610
drparamesh2@gmail.com
Dr Neeta Deshpande
Belgaum Diabetes centre
Department of Clinical research, Room No. NA, 2nd Floor, Maruti Galli,2nd Floor, Maruti Galli,-590001 Belgaum, KARNATAKA
Belgaum KARNATAKA
9880271313
neetarohit@gmail.com
Dr Manoj Chawla
BSES Muncipal General Hospital
Department of Clinical research, Room No. NA, BSES MG Hospital, 7th Floor Research Cabin, waiting area, Opposite railway station, SV Road, Andheri (W), Mumbai 58
Mumbai MAHARASHTRA
9820002333
linadiabetesresearch@gmail.com
Dr Bipin sethi
CARE HOSPITALS
Department of Clinical research, Room No. NA, ROAD NO. 1 PREM NAGAR BANJARA HILLS HYDERABAD TELANGANA 500034
Hyderabad TELANGANA
9440739238
sethibipin54@gmail.com
DR A G Unnikrishnan
Chellaram Diabetes lnstitute
Department of Clinical research, Room No. NA, 1st floor, Lalani Quantum, Pune-Bangalore NH 4. Bavdhan (Budruk) Pune, Maharashtra, India-411021
Pune MAHARASHTRA
8605011934
uagcdi@cdi.org.in
Dr Sharat Kolke
CRITICARE ASIA MULTISPECIALITY HOSPITAL
Department of Clinical research, Room No. NA, KOHINOOR CITY, CRITICARE ASIA MULTI SPECIALITY HOSPITAL, KURLA WEST, MUMBAI, MAHARASHTRA 400070
Mumbai MAHARASHTRA
9820059062
sharatkolke@hotmail.com
Dr Vaishali Deshmukh
Deenanath Mangeshkar Hospital and Research center
Department of Clinical research, Room No. NA, Deenanath Mangeshkar Hospital and Research center Pune, Super speciality Building, ground floor, Endocrinology Department, Erandwane Pune- 411004.
Pune MAHARASHTRA
9850811450
docvaishali@yahoo.co.in
Dr Dhrumil Patel
Dhrumils Hospital
Department of Clinical research, Room No. NA, Hari darshan cross roads, avani icon-301, kathwada road, vasant vihar-2,naroda, abad382330
Ahmadabad GUJARAT
9724410751
dhrumil.synergy@gmail.com
Dr Banshi Saboo
Dia care Research
Department of Clinical research, Room No. NA, 1-2, Gandhi Park, Near Nehru Nagar Cross Road, Ambawadi, Ahmedabad-380015, Gujarat, India
Ahmadabad GUJARAT
9824047676
banshisaboo98@gmail.com
Dr Nikita Doshi
Doshis Diabtes and Endocrine center
Department of Clinical research, Room No. NA, Doshis Diabtes and Endocrine center Behind Tourist hotel, New Shahupuri, Kolhapur, Maharashtara India- 416001
Kolhapur MAHARASHTRA
9673990305
nikitadoshict@gmail.com
Dr K D Modi
Dr MODIS CLINIC ( ADARSH NAGAR )
5-9-22/51,Beside Birla Temple Hill fort, Hyderabad- 500063
Hyderabad TELANGANA
9848115322
drmodisclinic@gmail.com
Dr Vijay Sekhar Reddy
GANDHI MEDICAL COLLEGE AND HOSPITAL
Department of Clinical research, Room No. NA, BHIOGUDA ROAD M.I.G.H COLONY MUSHEERABAD WALKER TOWN PADMARAO NAGAR SECUNDERABAD TELANGANA 500025
Hyderabad TELANGANA
9849172161
drdvsreddyendo@yahoo.com
DR Rizwan Ahmed Ansari
Hopewell Hospital
Department of Clinical research, Room No. NA, G-101, Sueml8, Ajit mill Cross Road, Ahmedabad, Gujarat, 380023
Ahmadabad GUJARAT
9033884736
drrizwanansari@yahoo.com
Dr Mahesh Rath
Kalinga Hospital Ltd
Department of Clinical research, Room No. NA, Kalinga Hospital Limited, Chandrasekharpur, Bhubneshwar 751023
Khordha ORISSA
9938099079
dr.maheshrath@gmail.com
Dr Nirav Shah
Kiran Multi Super Speciality Hospital and Research centre
Department of Clinical research, Room No. NA, Kiran Multi Super Speciality Hospital and Research centre, Near Sumul Dairy, Surat 395004
Surat GUJARAT
8320117490
drniravrshah@outlook.com
Dr Ketan Mehta
Kkasturi Medicare PVT LTD
Department of Clinical research, Room No. NA, Harshniketan, Gaondevi Road, Near Navrang Hotel, Bhayendar West, Thane, Maharashtra- 401101
Thane MAHARASHTRA
8356003006
drketanmehta04@gmail.com
Dr Manojitketan Mukhopadhyay
Life Line Diagnostics Centre Cum Nursing Home
Department of Clinical research, Room No. NA, 4A, Wood street, Kolkata-700016, West Bengal, India
Kolkata WEST BENGAL
9830203242
mkmukhopadhyay@yahoo.co.in
Dr Prabhat Kumar Sharma
Maharaja Agrasen Superspeciality Hospital
Department of Clinical research, Room No. NA, Sector-7, Central Spine, Vidyadhar Nagar, Jaipur-302039, Rajasthan, India
Jaipur RAJASTHAN
9983995050
pksharma.clinical@gmail.com
Dr Dinesh Agarwal
Marwari Hospitals
Department of Clinical research, Room No. NA, SJ Road, Athgaon, Guwahati-781008, Assam, India
Golaghat ASSAM
9864061456
drdinesh944@gmail.com
Dr Pankaj Aneja
Naveda Healthcare Center
Department of Clinical research, Room No. NA, Sector 8 pocket A1 house no: 81rohini Delhi.85 – 110085
New Delhi DELHI
9811117266
drpankajaneja@gmail.com
Dr Vaibhav Kothari
Navmeet Memorial Hospital "Sushrusha"
Department of Clinical research, Room No. NA, Opp. Sardar Patel Seva Samaj Hall, In lane, Opp. Navrangpura Telephone Exchange, Off. C. G. Road, Navrangpura, Ahmedabad-380006.
Ahmadabad GUJARAT
9979700995
drvaibhavkotharicr@gmail.com
Dr Mayura Choudhari
Oriion Criticare Super Speciality Hospital
Department of Clinical research, Room No. NA, 5-5-70, Opp. Kalash Mangal Karyalaya, Osmanpura, Chhatrapati Shambhaji Nagar, 431005, Maharastra, India
Aurangabad MAHARASHTRA
9422713734
kalediabetesclinic@gmail.com
DrRama Walia
PGIMER
Department of Clinical research, Room No. NA, Maghyamarg, sector-12, chandigarh-160012
Chandigarh CHANDIGARH
9872997438
ramawalia@rediffmail.com
Dr Himanshu Prajapati
PHC Prajna Healthcare
Department of Clinical research, Room No. NA, 205-208, 2nd floor, Aagam Avenue, Nr Adani CNG Pump, Sabarmati, Ahmedabad, Gujarat 380005
Ahmadabad GUJARAT
9925075607
drhimanshupcr@gmail.com
Dr Dhruvi Hasnani
RIMS Hospital
Department of Clinical
research, Room No.
NA, RIMS SUPERSPECIALITY HOSPITAL, 1ST FLOOR rupala complex, opp. Icici Bank, Near Ghodasar, Brts stop, Ghodasar, Ahmedabad, 380050.
Ahmadabad GUJARAT
8758485703
dhruvi.hasnani@gmail.com
Dr Prabhat Agarwal
S. N. Medical College & Hospital
Department of Clinical research, Room No. NA, Near Moti kotra, Mantola, Agra, U.P 282003
Agra UTTAR PRADESH
9319250485
prabhatagrawal321@gmail.com
Dr Hemant Phatale
SAMRAT ENDOCRINE INSTITUTE
Department of Clinical research, Room No. NA, 60, NEW ROKADIYA HANUMAN COLONY, CHATRAPATI SAMBHAJINAGAR, MUMBAI
Mumbai MAHARASHTRA
9823896796
hphatale@gmail.com
Dr Ritesh Agrawala
Shanti Pawan Multispeciality Care
Department of Clinical research, Room No. NA, Plot No. 1128/2658, Jayadurganagar, Bomikhal, Bhubneswar, Odisha-751010- India
Khordha ORISSA
8480500080
drriteshagr@gmail.com
Dr Kushal Banger
Shivam Hospital
Department of Clinical research, Room No. NA, Plot no -57, C.R.W CHS, Near MIDC, water Tank, Kalyan road, Dombivli East, Mumbai 421201 Maharashtra, India
Mumbai MAHARASHTRA
Institutional Ethics Committee, Deenanath Mangeshkar Hospital and research center, P, Dr. Vaishali Deshmukh
Approved
Institutional Ethics Committee, Gandhi Medical College and Hospital, Dr. Vijay Sekhar Reddy
Approved
Institutional Ethics Committee, Life Line Diagnostics Centre Cum Nursing Home, Dr Manojitketan Mukhopadhyay
Approved
Institutional Ethics Committee, S. N. Medical College & Hospital, Dr. Prabhat Agarwal
Approved
Kalinga Hospital Ethics Committee, Dr Mahesh Rath
Approved
Kiran Hospital Ethics Committee, Dr. Nirav Shah
Approved
Lakeview Ethics Committee, Dr Neeta Deshpande
Approved
Medisys Clinisearch Ethical Review Board, Dr Paramesh Shamanna
Approved
Oriion Criticare Hospital- Institutional Ethics Committee, Dr. Mayura Choudhari
Approved
Riddhi Medical Nursing Home IEC, Dr. Himanshu Prajapati
Approved
Rudraksh Hospital Ethics Committee, Dr. Dhruvi Hasnani
Approved
S2J Independent Ethics Committee, Dr. K D Modi
Submittted/Under Review
Sangini Hospital Ethics Committee, DR. Rizwan Ahmed Ansari
Approved
Shah Lifeline Hospital And Heart Institute Ethics Committee, DR. Dilip Shah
Approved
Shah Lifeline Hospital And Heart Institute Ethics Committee, Dr. Ketan Mehta
Approved
Sir Gangaram Hospital Ethics Committee, Dr. Ajay Agrawal
Submittted/Under Review
Zenith Institutional Ethics Committee, Dr Nikita Doshi
Approved
Regulatory Clearance Status from DCGI
Status
Approved/Obtained
Health Condition / Problems Studied
Health Type
Condition
Patients
(1) ICD-10 Condition: E00-E89||Endocrine, nutritional and metabolic diseases,
Intervention / Comparator Agent
Type
Name
Details
Comparator Agent
Semaglutide-Reference (R)
Dose Formulation: single-dose solution for injection in prefilled
pen
Unit Dose Strengths: Wegovy 0.25 mg FlexTouch (Semaglutide solution for injection in prefilled pen, 0.68 mg/mL, 1.5 mL), Wegovy 0.5 mg FlexTouch (Semaglutide solution for injection in prefilled pen, 1.34 mg/mL, 1.5 mL or 0.68 mg/mL, 3 mL), Wegovy 1 mg FlexTouch (Semaglutide solution for injection in prefilled pen, 1.34 mg/mL, 3 mL), Wegovy 1.7 mg FlexTouch (Semaglutide
solution for injection in prefilled pen, 2.27 mg/mL, 3 mL), Wegovy 2.4 mg FlexTouch (Semaglutide solution for injection in prefilled pen, 3.2 mg/mL, 3 mL)
Dosage Levels: Once weekly
Timing of Dose: At any time of day, with or without meal
Route of Administration: Subcutaneous
Duration of Dose: 24 weeks
Intervention
Semaglutide-Test (T)
Dose Formulation: single-dose solution for injection in pre-filled pen
Unit Dose Strengths: Semaglutide Injection 0.68 mg/mL, 1.5 mL (0.25 mg dose) Semaglutide Injection 1.34 mg/mL, 1.5 mL (0.5 mg dose), Semaglutide Injection 1.34 mg/mL, 3 mL (1 mg dose), Semaglutide Injection 2.27 mg/mL, 3 mL (1.7 mg dose), Semaglutide Injection 3.2 mg/mL, 3 mL (2.4 mg dose)
Dosage Levels: Once weekly
Timing of Dose: At any time of day, with or without meal
Route of Administration: Subcutaneous
Duration of Dose: 24 weeks
Inclusion Criteria
Age From
18.00 Year(s)
Age To
65.00 Year(s)
Gender
Both
Details
1) Must sign an ICF indicating that the participant understands the purpose of, and procedures
required for the study as described in Appendix 10.1.3 and in this protocol and is willing to
participate in the study.
2) Male or female participants with Age of 18 to 65 years (both inclusive) at the time of signing
the informed consent.
3) Body Mass Index (BMI) greater than or equal to 30 kg per m2 (Obese). OR BMI greater than or equal to 27 kg per m2 to less than 30 kg per m2 (overweight) in the presence of at least one weight-related comorbidity e.g. dysglycaemia (prediabetes or type 2 diabetes mellitus), hypertension, dyslipidaemia, obstructive sleep apnoea or cardiovascular disease at screening assessment.
4) Participants with Type 2 diabetes mellitus should additionally meet the following: Glycosylated Haemoglobin (HbA1c) greater than or equal to 7.5 percentage and less than 10.5 percentage at screening assessment. Participants who are on a stable treatment with metformin, sulphonylurea (SU) or metformin plus SU for at least 90 days before screening along with diet and exercise control.
5) History of at least one self-reported unsuccessful dietary effort to lose body weight.
6) Willing to comply with the dietary and physical activity requirement during the study.
7) Contraceptive use by participants or participant’s partners should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies. A female participant is eligible to participate if she is not pregnant or breastfeeding, and at least one of the following conditions applies: Is not a woman of childbearing potential (WOCBP) as defined in Appendix 4 OR Is a WOCBP and agrees to remain on an acceptable contraceptive method that is highly
effective (with a failure rate of less than 1 percentage per year), preferably with low user dependency
when used consistently and correctly, as described in Appendix 4 during the intervention
period and for at least 2 months after the last dose of the study intervention. The
investigator should evaluate the effectiveness and the potential for contraceptive method
failure (e.g., noncompliance, recently initiated) of the contraceptive method in relation
to the first dose of the study intervention. A WOCBP agrees not to donate eggs (ova, oocytes), freeze them for future use for
reproduction or retrieve them for their use during the recommended period of
contraception. A WOCBP agrees to seek advice about donation and cryopreservation of
germ cells. A WOCBP must have a negative highly sensitive serum B-human chorionic
gonadotropin (BhCG) test at screening and urine BhCG test at Baseline. If a urine test cannot be confirmed as negative (e.g., an ambiguous result), a serum pregnancy test is required. In such cases, the participant must be excluded from
participation if the serum pregnancy result is positive. Additional requirements for pregnancy testing during and after study intervention are
located in section 8.3.5. The investigator is responsible for review of medical history, menstrual history, and recent
sexual activity to decrease the risk of inclusion of a woman with early undetected pregnancy.
8) Male participants are eligible to participate if they agree to the following during the intervention period and for at least 2 months after the last dose of study intervention: Must agree not to plan to father a child or donate sperm for reproduction; PLUS, either of the following: Be abstinent from heterosexual intercourse as their preferred and usual lifestyle (abstinent on a long-term and persistent basis) and agree to remain abstinent; OR Must agree to use contraception barrier as detailed below: a male participant must wear a condom when engaging in any activity that allows for the passage of ejaculate to another person With female partner use of an additional highly effective contraceptive method with a failure rate of less than 1 percentage per year as described in Appendix 4
9) The participant with adequate haematologic, liver renal function and other parameters as
mentioned below, at screening assessment.
a) Calcitonin less than or equal to 50 ng per L
b) Blood amylase less than or equal to 3 into ULN
c) Blood lipase less than or equal to 3 into ULN
d) Alkaline phosphatase less than or equal to 2 into ULN
e) Alanine aminotransferase less than or equal to 2 into ULN
f) Aspartate aminotransferase less than or equal to 2 into ULN
g) Total bilirubin less than or equal to 1.5 into ULN
h) Estimated glomerular filtration rate (eGFR) greater than 30ml per min per 1.73m2 as assessed by CKD-EPI 2021 equation including participants with end-stage renal disease
i) Haemoglobin greater than or equal to 9 g per dL
j) WBC count greater than or equal to 2500 per cu.mm
k) Neutrophil count greater than or equal to 1500 per cu.mm
l) Platelet count greater than or equal to 100,000 per cu.mm
ExclusionCriteria
Details
1) Known allergies, hypersensitivity, or intolerance to any of the study interventions & other GLP- 1 receptor agonists or components excipients thereof (refer to the SmPC of
Wegovy) or drug or other allergies that, in the opinion of the investigator, contraindicate
participation in the study.
2) Contraindications or limitations for administration of investigational intervention
according to SmPC of Wegovy.
Obesity related:
3) Treatment with any medication for the indication of obesity AND any medications affecting weight (other than oral contraceptives) within the past 90 days before screening.
4) A self-reported change in body weight greater than 5 kg (11 lbs) within 90 days before screening irrespective of medical records.
5) Previous or planned (during the study period) obesity treatment with surgery or a weight loss device. However, the following are allowed: (a) liposuction and or abdominoplasty, if performed greater than 1 year before screening, (b) lap banding, if the band has been removed greater than 1 year before screening, (c) intragastric balloon, if the balloon has been removed greater than 1 year before screening or (d) duodenal-jejunal bypass sleeve, if the sleeve has been removed greater than 1 year before screening.
Diabetes related:
6) Treatment with any medication for the indication of diabetes other than stated in the inclusion criteria within the past 90 days prior day of screening & treatment with GLP 1 RA within the past 180 days prior to screening.
7) Diagnosis of Type 1 diabetes.
8) Have a history of acute diabetic complications (diabetic ketoacidosis, lactic acidosis or
hyperosmolar hyperglycaemic state) within 6 months before screening.
9) History of proliferative retinopathy or diabetic macular oedema, or any other unstable retinopathy (rapidly progressive) recorded in medical history and may require treatment during the study.
Non-diabetic participants:
10) HbA1c greater than or equal to 5 percentage as measured at screening.
Mental health:
11) Suicidal ideation corresponding to a yes answer on Question 4 or 5 on the Suicidal
Thoughts portion of the Columbia-Suicide Severity Rating Scale (C-SSRS) within the past 30 days before screening.
12) History of major depressive disorder within 2 years before screening.
13) Diagnosis of other severe psychiatric disorder (e.g., schizophrenia, bipolar disorder).
14) Any lifetime history of a suicidal attempt.
15) Suicidal behaviour within 30 days before screening corresponding to a “yes” answer to any
of the suicide-related behaviours (actual attempt, interrupted attempt, aborted attempt,
preparatory act or behaviour) on the Suicidal Behaviour portion of the C-SSRS.
16) Patient Health Questionnaire-9 (PHQ-9) score of greater than or equal to 15 at screening.
General safety:
17) Presence of hepatitis B surface antigen (HBsAg) at screening or within 3 months prior to
the first dose of investigational intervention.
18) Positive hepatitis C antibody test result at screening or within 3 months prior to the first
dose of investigational intervention.
19) Has known human immunodeficiency virus (HIV) seropositive status, or positive HIV antibody test at screening.
20) Family or personal history of multiple endocrine neoplasia Type 2 or medullary thyroid
carcinoma. Family is defined as a first degree relative.
21) Participants with a history of acute chronic pancreatitis
22) Participants with known alcohol or other substance abuse within last 1year of screening.
23) History or presence of malignancy within the past 5 years except for adequately treated
cervical carcinoma in situ, basal cell or squamous cell skin cancer.
24) Participant with uncontrolled hypertension with sitting systolic BP greater than or equal to 160 mmHg and per or diastolic BP greater than or equal to 100 mmHg at screening.
25) Participant with clinically significant current or recent (within the past 60 days prior to screening) cardiac conditions as defined below:
a) Acute coronary syndrome, stroke [including transient ischemic attack (TIA)] or other
ischemic event or thromboembolic event [e.g., deep vein thrombosis (DVT), pulmonary
embolism]
b) Clinical risk assessment of cardiac function using the New York Heart Association
Functional Classification of Class III & IV26
26) Received any other investigational intervention or used an invasive investigational medical
device within 3 months or 5 half-lives prior to the first dose of study intervention,
whichever is longer.
27) Previous treatment with semaglutide.
28) Participants with medication history of herbal non-herbal medicine with unknown
unspecified content within 90 days.
29) Participants with any abnormality on 12-lead ECG at screening that in the opinion of the Investigator is clinically significant and is judged as potential risk for his her participation in the study.
30) Surgery scheduled for the duration of the study, except for minor surgical procedures, in the opinion of the investigator.
31) Participation in another clinical study within 90 days before screening.
32) Documented medical history of uncontrolled, clinically significant intercurrent medical
condition(s) for which, in the opinion of the investigator, participation would not be in the
best interest of the participant (e.g., compromise the well-being) or that could prevent, limit,
or confound the protocol-specified assessments.
33) Other causes of obesity can be excluded with documented history or known case of other
endocrine diseases, including hypothalamic obesity, pituitary obesity, Cushings syndrome,
acromegaly, hypogonadism etc.
Method of Generating Random Sequence
Computer generated randomization
Method of Concealment
On-site computer system
Blinding/Masking
Open Label
Primary Outcome
Outcome
TimePoints
To establish non-inferiority of semaglutidetest
compared to semaglutide-reference in
overweight and obese adult participants in
adjunct to diet and exercise
Percent change in the body weight from
baseline to Week 24
Secondary Outcome
Outcome
TimePoints
To establish non- inferiority of Semaglutide-
Test compared to semaglutide-reference in
overweight & obese adult participants in
adjunct to diet & exercise
a) Percent change in body weight from baseline to Week 4, 8, 12, 16 & 20
b) Mean change in absolute body weight from
baseline to Week 4, 8, 12, 16, 20 & 24.
c) Percentage of participants who achieve greater than or equal to 5 percentage, greater than or equal to 10 percentage body weight loss at Week 4, 8, 12, 16 & 24
d) Mean change in BMI from baseline to Week 4, 8, 12, 16, 20 & 24
e) Mean change in body waist circumference (cm) from baseline to Week 4, 8 12, 16, 20 & 24
To evaluate safety of semaglutide-test
compared to semaglutide-reference in
overweight and obese adult participants in
adjunct to diet and exercise
Percentage of participants experiencing TEAE
To evaluate immunogenicity of
semaglutide-test compared to semaglutidereference
in overweight & obese adult
participants in adjunct to diet & exercise
Proportion of participants with anti-drug
antibodies (ADA) & neutralizing antibody
(NAb) [Timeframe: Baseline (Pre-dose), Week
12, 20 & 24]
Target Sample Size
Total Sample Size="264" Sample Size from India="264" Final Enrollment numbers achieved (Total)= "Applicable only for Completed/Terminated trials" Final Enrollment numbers achieved (India)="Applicable only for Completed/Terminated trials"
Phase of Trial
Phase 3
Date of First Enrollment (India)
02/07/2025
Date of Study Completion (India)
Applicable only for Completed/Terminated trials
Date of First Enrollment (Global)
Date Missing
Date of Study Completion (Global)
Applicable only for Completed/Terminated trials
Estimated Duration of Trial
Years="0" Months="6" Days="0"
Recruitment Status of Trial (Global)
Not Applicable
Recruitment Status of Trial (India)
Not Yet Recruiting
Publication Details
N/A
Individual Participant Data (IPD) Sharing Statement
Will individual participant data (IPD) be shared publicly (including data dictionaries)?
Response - NO
Brief Summary
This is a study to Investigate the Efficacy and Safety of Semaglutide of Intas Compared to Wegovy FlexTouch in Overweight and Obese Adult Participants in Adjunct to Diet and Exercise.